Corporate News Report – Sarepta Therapeutics (SRPT)
Trading Performance (as of 11:29 AM CET, Wednesday 21 May 2026)
- Closing price: $19.17 per share.
- 24‑hour change: +8.12 %.
- Volume traded in the last 24 hours: $63.7 million.
- Market capitalization: $1.9 billion.
- Outstanding shares: 105.5 million.
- Simple moving average (200 days): $18.88.
- 52‑week high: $24.68 (26 January 2026).
- 52‑week low: $14.68 (11 June 2026).
- Price trend since the previous month‑end: -4.82 %.
Related Stock Activity (last 24 hours)
| Symbol | Company | 24‑hour % | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| VERX | Vertex | +5.84 % | $14.32 | $2.2 bn | 610.91 |
| HOS | Hornbeck Offshore Services I | -2.49 % | $6.66 | $2.2 bn | 0.94 |
| MBIN | Merchants | +1.70 % | $48.42 | $2.2 bn | 9.53 |
| FLYW | Flywire | +2.59 % | $18.64 | $2.2 bn | 70.18 |
| HRMY | Harmony Biosciences | +3.09 % | $38.70 | $2.2 bn | 12.21 |
Flywire Earnings Announcement Flywire (FLYW) will release its third‑quarter 2026 financial results after market close on 3 November 2026. A conference call will be held at 5:00 p.m. Eastern Time, featuring CEO Mike Massaro, President/COO Rob Orgel, and CFO Cosmin Pitigoi. The call will be webcast on Flywire’s investor‑relations website with a replay available later.
Company Overview – Sarepta Therapeutics Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on RNA‑based therapeutics for rare and infectious diseases. The company develops and commercializes treatments intended to address unmet medical needs worldwide.
